OptimizeRx (OPRX) Cash from Financing Activities (2010 - 2026)

OptimizeRx has disclosed Cash from Financing Activities across 13 years of filings, most recently posting -$4.7 million for Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 3.44% year-over-year to -$4.7 million; the TTM figure through Jun 2026 stood at -$11.1 million (down 31.08% YoY), while the FY2025 annual figure was -$8.8 million, down 79.15% from the prior year.
• Cash from Financing Activities came in at -$4.7 million for Q2 2026 at OptimizeRx, down from -$2.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $36.2 million in Q4 2023 to a low of -$12.0 million in Q3 2022.
• Average Cash from Financing Activities over 5 years is -$655987.6, with a median of -$777500.0 recorded in 2024.
• The largest YoY upside for Cash from Financing Activities was 586.46% in 2023 against a maximum downside of 3080.6% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$7.4 million in 2022, then jumped by 586.46% to $36.2 million in 2023, then slumped by 107.8% to -$2.8 million in 2024, then retreated by 22.1% to -$3.4 million in 2025, then plunged by 35.15% to -$4.7 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$4.7 million in Q2 2026, -$2.7 million in Q1 2026, and -$3.4 million in Q4 2025.